Apimeds Pharmaceuticals US (APUS) Stock: Buy, Sell, or Hold?
$2.27
-0.09 (-3.81%)
βΌ
5d:
-16.85%
30d:
-50.44%
90d:
-50.11%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (75%)
Quality Score
51/100
Position
OVERSOLD
30-Day Fair Range
$2.45 β $4.98
Position: OVERSOLD
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$2.20 / $3.11
Trend: Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
βΈοΈ WAIT FOR STABILIZATION: APUS is down 16.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Get Alerted When APUS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: APUS is currently trading at $2.27, which is considered oversold relative to its 30-day fair value range of $2.45 to $4.98.
Technical Outlook: Technically, APUS is in a uptrend. Immediate support is located at $2.20, while resistance sits at $3.11. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, APUS is in a uptrend. Immediate support is located at $2.20, while resistance sits at $3.11. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.45 -
$4.98
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.7%
Trading Range & Key Levels
30-Day Trading Range
$2.45 -
$4.98
Current vs Trading Range
OVERSOLD
Support Level
$2.20
Resistance Level
$3.11
Current Trend
Uptrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (50/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.8%)
- WARNING: Composite score 51/100 in the bottom quintile β this cohort historically lags the market
Fundamental Context
Share APUS Analysis
Share this live APUS analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (APUS)
Bullish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Oct 28, 2026
Daily AI digest
AI Retail Discussion Summary:
One bullish StockTwits message was posted expressing confidence in the $APUS stock.
Key Retail Themes:
Buyer confidence
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 13, 2026 4:48 AM ET
Data refreshes hourly during market hours. Next update: 5:48 AM
Data refreshes hourly during market hours. Next update: 5:48 AM
π₯ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is APUS showing a specific setup today?
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I⦠|
STRONG BUY
29 analysts |
$208 | 23 SELL |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$58 | 41 HOLD |
|
AQST
Aquestive Therapeutics I⦠|
STRONG BUY
9 analysts |
$9 | 60 BUY |
|
TEVA
Teva Pharma Industries L⦠|
STRONG BUY
15 analysts |
$49 | 36 SELL |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$63 | 51 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive APUS Research Pages